Providing Thought Leadership / April 1, 2021
During the pandemic, large numbers of residents were prescribed drugs investigated for COVID-19 treatment, and an increase in prescribing of antibiotics commonly used for respiratory infections was observed in more than 1,900 US nursing homes. Prescribing of these drugs may increase the risk of adverse events, without providing clear benefits. Surveillance of nursing home prescribing practices is critical to evaluate concordance with guideline-recommended therapy and improve resident safety.
A newly published study, “Trends in Prescribing of Antibiotics and Drugs Investigated for COVID-19 Treatment in U.S. Nursing Home Residents During the COVID-19 Pandemic” in Clinical Infectious Disease, a journal of the Infectious Disease Society of America, by Marti Wdowicki, PharmD, Director of Clinical Operations, South; Mary Beckerson, MS, Manager, Client Reporting and Analytics; and Stephen Creasy, PharmD, Director, Clinical Services, stemmed from the PharMerica’s ongoing work with the Centers for Disease Control (CDC) to provide surveillance data to help inform their guidance.
Read the full study here.
Filed under: Providing Thought Leadership